
Please try another search
Statera BioPharma, Inc., formerly Cytocom, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies targeting autoimmune, neutropenia/anemia, viruses and cancers. Its Advanced Immunomodulating Multi-component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200, STAT-400 and STAT-600 AIMS programs. Its STAT-200 program includes STAT-201, STAT-205, STAT-203 and STAT-202. STAT-201 is focused the treatment of Crohn’s disease. STAT-205 is focused on treatment of acute and post-acute coronavirus (COVID 19). Its STAT-400 programs include STAT-401 and STAT-400. STAT-401 is an injectable pentapeptide that is targeted for patients with pancreatic cancer.
Name | Age | Since | Title |
---|---|---|---|
Michael Kevin Handley | 50 | 2021 | CEO, President & Chairman of the Board |
Satish Chandran | - | 2022 | Director |
Uday Saxena | 64 | 2022 | Independent Director |
Blake Hawley | - | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review